Industry

EINDHOVEN, the Netherlands & LAUSANNE, Switzerland & BOSTON–(BUSINESS WIRE)–ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announced it will publish half-year 2022 financial and operating results on Tuesday, September 27, 2022. Management will host a webcast to discuss … [Read more…]

PXL065 Phase 2 trial for the treatment of NASH met its primary efficacy endpoint for liver fat content reduction at 36-weeks for all doses. Histology findings from paired liver biopsies showed strong improvement in fibrosis without worsening of NASH, consistent with dose-dependent reduction of all biomarkers related to fibrogenesis and fibrosis risk scores; improvement seen … [Read more…]

SEATTLE–(BUSINESS WIRE)–Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the pricing of its underwritten public offering of 13,606,000 shares of its common stock pursuant to its existing shelf registration statement. The shares of common stock are being offered at … [Read more…]

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that the Company has successfully got listed on the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange (SSE), making InnoCare the double-listed biotechnology company on the Hong Kong Stock Exchange (HKEx) and … [Read more…]

  NASHVILLE, Tenn.–(BUSINESS WIRE)–Yesterday, the U.S. District Court for the District of Columbia issued an opinion and final appealable order denying the request made by the U.S. Department of Justice and the States of New York and Minnesota for the Court to enjoin UnitedHealth Group Incorporated (NYSE: UNH) (“UnitedHealth Group”) from acquiring Change Healthcare Inc. … [Read more…]

TORONTO–(BUSINESS WIRE)–Jack Nathan Medical Corp. (TSXV: JNH, OTCQB: JNHMF) (“Jack Nathan Health”, “JNH” or the “Company”) announces that David Berman stepped down from his position as Chief Financial Officer of the Company effective as September 19, 2022. “On behalf of myself and the board of directors, we want to thank David for his contributions to … [Read more…]

CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, Inc. (NYSE American: RMED) (“Ra Medical” or the “Company”) announces that at its virtual Special Meeting of Stockholders held today, the Company’s stockholders approved all three proposals on the proxy filed with the Securities and Exchange Commission on August 29, 2022. The Company also announces that its Board of Directors … [Read more…]

MARLBOROUGH, Mass.–(BUSINESS WIRE)–#IOLT–Market leading innovator in laboratory digital transformation, Scitara, has announced a partnership with Agilent, a leader in analytical and diagnostic technologies. The announcement enables the integration of Scitara’s Scientific Integration Platform SIP with Agilent’s Software and Informatics Division portfolio of products, including chromatography software and lab workflow management solutions. Scitara’s SIP provides a … [Read more…]

ST. PAUL, Minn.–(BUSINESS WIRE)–Ecolab will host a live webcast of its third quarter earnings conference call to discuss 2022 third quarter results. A news release containing third quarter results is expected to be issued before market open on November 1, 2022. Details for the public webcast are as follows: TIME: 1:00 p.m. Eastern Time DATE: … [Read more…]

FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire MiroBio, a privately held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, for approximately $405 million in cash. The acquisition provides Gilead with MiroBio’s proprietary discovery platform and entire portfolio … [Read more…]